• Molecular NameFlavoxate
  • SynonymFlavoxate HCI; Flavoxate HCL
  • Weight391.467
  • Drugbank_IDDB01148
  • ACS_NO15301-69-6
  • Show 3D model
  • LogP (experiment)4.636
  • LogP (predicted, AB/LogP v2.0)4.32
  • pka7.3
  • LogD (pH=7, predicted)3.02
  • Solubility (experiment)0.00999 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.81
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA55.84
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.
  • Absorption_valueN/A
  • Absorption (description)Well absorbed from gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFlavoxate is rapidly hydrolized in plasma to its major active metabolite 3-methylflavone-8-carboxylic acid, MFCA.
  • Half lifeN/A
  • Excretion57% of the flavoxate HCl was excreted in the urine within 24 hours.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.
  • LD50 (rat)4273 mg/kg
  • LD50 (mouse)1837 mg/kg